90yttrium-ibritumomab-tiuxetan as first-line treatment for follicular lymphoma: 30 months of follow-up data from an international multicenter phase II clinical trial

Journal of Clinical Oncology

Volumn 31, Issue 3, 2013, Pages 308-313

  Scholz, Christian W ^a   Pinto, Antonello ^f   Linkesch, Werner ^g   Lindén, Ola ^h   Viardot, Andreas ^d   Keller, Ulrich ^b   Hess, Georg ^c   Lastoria, Secondo ^f   Lerch, Kristina ^a   Frigeri, Ferdinando ^f   Arcamone, Manuela ^f   Stroux, Andrea ^a   Frericks, Bernd ^a   Pott, Christiane ^e   Pezzutto, Antonio ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

^d UNIVERSITY OF ULM   (Germany)

^e UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^f NATIONAL CANCER INSTITUTE   (Italy)

^g MEDICAL UNIVERSITY OF GRAZ   (Austria)

^h LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

IBRITUMOMAB TIUXETAN; INDIUM 111; LACTATE DEHYDROGENASE; RITUXIMAB;

ADULT; AGED; ANEMIA; ARTICLE; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CARDIOVASCULAR DISEASE; CLINICAL EXAMINATION; COMPUTER ASSISTED TOMOGRAPHY; DOSIMETRY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; INFECTION; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOPENIA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; NEUTROPENIA; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; SKIN IRRITATION; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VEGETATIVE STAGE;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASM, RESIDUAL; PROPORTIONAL HAZARDS MODELS; RADIOIMMUNOTHERAPY; TIME FACTORS;

EID: 84873368418     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.41.1553     Document Type: Article

References (22)

1. Federico M, Molica S, Bellei M, et al: Prognostic factors in low-grade non-Hodgkin lymphomas. Curr Hematol Malig Rep 4:202-210, 2009
2. Solal-Céligny P, Roy P, Colombat P, et al: Follicular lymphoma international prognostic index. Blood 104:1258-1265, 2004 (Pubitemid 39166497)
3. Wilder RB, Tucker SL, Ha CS, et al: Doseresponse analysis for radiotherapy delivered to patients with intermediate-grade and large-cell immunoblastic lymphomas that have completely responded to CHOP-based induction chemotherapy. Int J Radiat Oncol Biol Phys 49:17-22, 2001 (Pubitemid 32042118)
4. Ghielmini M, Schmitz SF, Cogliatti SB, et al: Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly × 4 schedule. Blood 103:4416-4423, 2004 (Pubitemid 38745964)
5. Martinelli G, Schmitz SF, Utiger U, et al: Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. J Clin Oncol 28:4480-4484, 2010
6. Kaminski MS, Tuck M, Estes J, et al: 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 352:441-449, 2005 (Pubitemid 40175970)
7. Witzig TE, Gordon LI, Cabanillas F, et al: Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory lowgrade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 20:2453-2463, 2002 (Pubitemid 34525730)
8. Wiseman GA, Witzig TE: Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin) induces long-term durable responses in patients with relapsed or refractory B-Cell non-Hodgkin's lymphoma. Cancer Biother Radiopharm 20:185-188, 2005 (Pubitemid 40696100)
9. Morschhauser F, Radford J, Van Hoof A, et al Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma J Clin Oncol 26:5156-5164, 2008
10. Swerdlow ST, Campo E, Harris NL, et al WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France, International Agency for Research on Cancer, 2008
11. Cheson BD, Horning SJ, Coiffier B, et al Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas: NC Sponsored International Working Group. J Clin Oncol 17:1244, 1999
12. van Dongen JJ, Langerak AW, Bruggemann M, et al: Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 17:2257-2317, 2003 (Pubitemid 38072572)
13. Witzig TE, White CA, Wiseman GA, et al: Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20 (+) B-cell non-Hodgkin's lymphoma. J Clin Oncol 17:3793-3803, 1999
14. Marcus R, Imrie K, Belch A, et al: CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105:1417-1423, 2005 (Pubitemid 40223656)
15. Rummel MJ, Niederle N, Maschmeyer G, et al Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: Final results of a randomized phase III study of the STIL (Study Group Indolent Lymphomas, Germany). Blood 114, 2009 (abstr 405)
16. Salles G, Seymour JF, Offner F, et al: Rituxmab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): A phase 3, randomised controlled trial. Lancet 377:42-51, 2011
17. van Oers MH, Klasa R, Marcus RE, et al: Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: Results of a prospective randomized phase 3 intergroup trial. Blood 108:3295-3301, 2006 (Pubitemid 44794222)
18. Ladetto M, De Marco F, Benedetti F, et al: Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: The superior disease control of R-HDS does not translate into an overall survival advantage. Blood 111:4004-4013, 2008
19. Hiddemann W, Kneba M, Dreyling M, et al: Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106:3725-3732, 2005 (Pubitemid 41742196)
20. Czuczman MS, Emmanouilides C, Darif M, et al: Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy. J Clin Oncol 25:4285-4292, 2007 (Pubitemid 47548569)
21. Sacchi S, Marcheselli L, Bari A, et al: Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: A 16-year follow-up study. Haematologica 93:398-404, 2008 (Pubitemid 351398641)
22. Bernstein SH, Burack WR: The incidence, natural history, biology, and treatment of transformed lymphomas. Hematology Am Soc Hematol Educ Program 532-541, 2009